Physician profile
Mark Richard Needham
NPI 1578590659
$1,640.58
in general payments reported to CMS, 2019-2025
17 companies · $524 in 2025
The $524 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $442 · 2020: $143 · 2022: $39.92 · 2023: $219 · 2024: $273 · 2025: $524.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,016.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,015.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $574.59 | 2019-2025 | Evenity, Prolia |
| Lilly USA, LLC | $198.36 | 2019-2025 | Kisunla, Zepbound, Mounjaro |
| Novo Nordisk INC | $178.75 | 2019-2025 | Ozempic, Rybelsus |
| Cochlear Americas | $159.81 | 2025 | Cochlear Nucleus Ci632 Cochlear Implant With Slim Modiolar Electrode, Baha, Osia Osi300 Implant |
| Gilead Sciences, INC. | $138.26 | 2019-2023 | Descovy |
| Bayer Healthcare Pharmaceuticals INC. | $55.32 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $53.84 | 2024-2025 | Fasenra, Breztri |
| Glaxosmithkline, LLC. | $48.57 | 2023-2025 | Shingrix, Arexvy |
| Bausch Health US, LLC | $44.02 | 2024 | Aplenzin, Wellbutrin |
| Regeneron Healthcare Solutions, INC. | $39.92 | 2022 | |
| Alkermes, INC. | $28.62 | 2023 | Vivitrol |
| Hologic Sales and Service, LLC | $25.87 | 2025 | Thinprep 2000 Processor, Aptima |
| Noven Therapeutics, LLC | $24.08 | 2025 | Xelstrym |
| Sumitomo Pharma America, INC. | $22.42 | 2025 | Gemtesa |
| Janssen Scientific Affairs, LLC | $18.04 | 2020 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $17.00 | 2019 | |
| Pfizer INC. | $13.11 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Needham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.